Search peptides, terms, sources/
Research source · 2026

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
216 adults with obesity and at-risk MASLD, recruited in the United States and Spain
Sample size
216
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Correction status
Author correction published: Nature Medicine 2026 (DOI 10.1038/s41591-026-04650-w, PMID 42642663). Content of the correction not read.
Date checked
14 November 2026

Limitations

Short (48 weeks), two countries only, liver fat measured by imaging rather than biopsy outcomes. Funding statement not shown in the Europe PMC record; several authors are Boehringer Ingelheim staff. An author correction has been published (PMID 42642663); its content was not read.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.